Lilly to present 16 Alzheimer's abstracts at AAIC 2026, including Kisunla and P‑tau217 data

Conference scope

Lilly will present 16 abstracts at the Alzheimer's Association International Conference (AAIC) 2026 in London, July 12–15, comprising three oral presentations and 13 posters. Topics span imaging science, diagnostics, health economics, real‑world prescribing evidence, methodology, and patient‑centered outcomes.

Kisunla (donanemab‑azbt) clinical findings

New analyses from TRAILBLAZER‑ALZ 6 and the TRAILBLAZER‑ALZ 2 long‑term extension report safety data following modified titration and corticosteroid pretreatment, along with long‑term extension evidence on biomarkers and potential durability of clinical benefit. A Developing Topics session on July 15 will present these findings and related clinical questions.

Diagnostics—P‑tau217 blood assays

Oral data presented July 15 show P‑tau217 blood biomarker assays achieved strong rule‑in performance comparable to amyloid PET for identifying Alzheimer's pathology in cognitively unimpaired individuals, supporting a potentially more scalable alternative to specialized imaging in the future.

Methodology and additional research

On July 13 an oral session will address methodological approaches—external controls versus internal extrapolation—in assessing long‑term trial outcomes for TRAILBLAZER‑ALZ 2. Additional posters cover PET and diffusion tensor imaging endpoints, ARIA‑E incidence linked to florbetapir‑PET patterns, HEOR analyses of healthcare utilization and Medicare payments, and real‑world prescribing and registry analyses including a UK controlled access programme interim analysis.